世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

CD20ターゲット薬の世界市場成長 2023-2029


Global CD20 Target Drug Market Growth 2023-2029

LPI(LPインフォメーション)の最新調査によると、CD20ターゲット薬の世界市場規模は2022年に100万米ドルと評価されました。下流市場での需要の増加に伴い、CD20ターゲット薬は2029年までに100万米ドルの再調整規... もっと見る

 

 

出版社 出版年月 電子版価格 ページ数 言語
LP Information
LPインフォメーション
2023年11月7日 US$3,660
シングルユーザライセンス
ライセンス・価格情報・注文方法はこちら
148 英語

日本語のページは自動翻訳を利用し作成しています。


 

サマリー

LPI(LPインフォメーション)の最新調査によると、CD20ターゲット薬の世界市場規模は2022年に100万米ドルと評価されました。下流市場での需要の増加に伴い、CD20ターゲット薬は2029年までに100万米ドルの再調整規模になると予測され、レビュー期間中のCAGRは%です。
この調査レポートは、世界のCD20ターゲット薬市場の成長可能性を明らかにしています。CD20ターゲット薬は今後の市場でも安定した成長が期待されます。しかし、CD20標的薬の普及には、製品の差別化、コスト削減、サプライチェーンの最適化が引き続き重要です。CD20ターゲット医薬品市場がもたらす大きなビジネスチャンスを活かすためには、市場参入企業は研究開発への投資、戦略的パートナーシップの構築、消費者の嗜好の変化に合わせた製品提供を行う必要があります。
CD20は、通常Bリンパ球の表面に現れる細胞表面抗原である。CD20標的薬は、特定の種類のB細胞関連疾患の治療に使用される薬剤の一種である。これらの薬剤はCD20抗原を標的とすることにより、B細胞の生存と機能に影響を与えます。これらの薬剤は主にB細胞リンパ腫や自己免疫疾患の治療に使用される。
主な特徴
CD20ターゲット薬市場に関する本レポートは、様々な側面を反映し、業界に関する貴重な洞察を提供します。
市場規模と成長:この調査レポートは、CD20ターゲット薬市場の現在の規模と成長の概要を提供します。過去データ、タイプ別市場区分(CD20ターゲット、CD20+CD3ターゲットなど)、地域別内訳などが含まれます。
市場促進要因と課題:政府規制、環境問題、技術の進歩、消費者の嗜好の変化など、CD20ターゲット医薬品市場の成長を促進する要因を特定・分析することができます。また、インフラストラクチャーの制約、射程距離への不安、高額な初期費用など、業界が直面する課題も明らかにすることができます。
競合情勢:この調査レポートは、CD20標的薬市場内の競合状況の分析を提供しています。主要企業のプロフィール、市場シェア、戦略、製品提供などが含まれています。また、新興プレーヤーとその潜在的な市場への影響にもスポットを当てています。
技術開発:調査レポートは、CD20標的薬業界における最新の技術開発を掘り下げることができます。これには、CD20標的薬技術の進歩、CD20標的薬の新規参入、CD20標的薬の新規投資、CD20標的薬の将来を形作るその他の技術革新が含まれます。
川下企業の好み:本レポートは、CD20標的薬市場における顧客の購買行動や採用動向を明らかにします。このレポートには、顧客の購買意思決定やCD20標的薬製品の嗜好に影響を与える要因が含まれています。
政府の政策とインセンティブこの調査レポートは、CD20標的薬市場に対する政府の政策やインセンティブの影響を分析しています。これには、CD20標的薬市場の促進を目的とした規制の枠組み、補助金、税制優遇措置、その他の措置の評価が含まれます。また、市場成長促進におけるこれらの政策の有効性も評価します。
環境への影響と持続可能性CD20ターゲット薬市場の環境への影響と持続可能性の側面を評価します。
市場予測と将来展望:調査レポートでは、実施した分析に基づいて、CD20標的薬産業の市場予測と展望を提供しています。これには、市場規模、成長率、地域動向、技術進歩や政策展開に関する予測などが含まれます。
提言と機会本レポートは、業界関係者、政策立案者、投資家への提言で締めくくられています。市場関係者が新たなトレンドを活用し、課題を克服し、CD20標的薬市場の成長と発展に貢献するための潜在的な機会を強調しています。
市場の細分化
CD20ターゲット医薬品市場は、タイプ別と用途別に分類されます。2018年から2029年までの期間について、セグメント間の成長により、タイプ別、用途別の消費額の正確な計算と予測を数量と金額で提供します。
タイプ別セグメント
CD20ターゲット
CD20+CD3ターゲット
用途別セグメント
関節リウマチ
慢性リンパ性白血病
リンパ腫
その他
本レポートではまた、市場を地域別に分けています:
南北アメリカ
アメリカ
カナダ
メキシコ
ブラジル
APAC
中国
日本
韓国
東南アジア
インド
オーストラリア
ヨーロッパ
ドイツ
フランス
英国
イタリア
ロシア
中東・アフリカ
エジプト
南アフリカ
イスラエル
トルコ
GCC諸国
以下の企業は、主要な専門家から収集した情報、および企業のカバレッジ、製品ポートフォリオ、市場浸透度の分析に基づいて選択されています。
ロシュ
サノフィ
ノバルティス
TGセラピューティクス
アッヴィ
ジェンマブ
PTカルベ・ジェネキシン・バイオロジクス
アムジェン
ファイザー
サンド株式会社
セルトリオン社
バイオキャドメディカル
mAbxience SA
ヘテロドラッグス
アリョーゲンファーマ
バイオシダスSA
プロバイオメッドSAデCV
ヘンリアス
イノベント
チアタイ・ティアノイング
CASIファーマシューティカルズ
シノセルテック
バイオレイ
本レポートで扱う主な質問
CD20標的薬の世界市場の10年見通しは?
CD20標的薬の世界市場および地域別市場成長の要因は何か?
市場別、地域別に最も急成長する技術は何か?
CD20標的薬の市場機会は最終市場規模によってどのように異なるのか?
CD20標的薬のタイプ別、用途別内訳は?


ページTOPに戻る


目次

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global CD20 Target Drug Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for CD20 Target Drug by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for CD20 Target Drug by Country/Region, 2018, 2022 & 2029
2.2 CD20 Target Drug Segment by Type
2.2.1 CD20 Target
2.2.2 CD20+CD3 Target
2.3 CD20 Target Drug Sales by Type
2.3.1 Global CD20 Target Drug Sales Market Share by Type (2018-2023)
2.3.2 Global CD20 Target Drug Revenue and Market Share by Type (2018-2023)
2.3.3 Global CD20 Target Drug Sale Price by Type (2018-2023)
2.4 CD20 Target Drug Segment by Application
2.4.1 Rheumatoid Arthritis
2.4.2 Chronic Lymphocytic Leukemia
2.4.3 Lymphoma
2.4.4 Other
2.5 CD20 Target Drug Sales by Application
2.5.1 Global CD20 Target Drug Sale Market Share by Application (2018-2023)
2.5.2 Global CD20 Target Drug Revenue and Market Share by Application (2018-2023)
2.5.3 Global CD20 Target Drug Sale Price by Application (2018-2023)
3 Global CD20 Target Drug by Company
3.1 Global CD20 Target Drug Breakdown Data by Company
3.1.1 Global CD20 Target Drug Annual Sales by Company (2018-2023)
3.1.2 Global CD20 Target Drug Sales Market Share by Company (2018-2023)
3.2 Global CD20 Target Drug Annual Revenue by Company (2018-2023)
3.2.1 Global CD20 Target Drug Revenue by Company (2018-2023)
3.2.2 Global CD20 Target Drug Revenue Market Share by Company (2018-2023)
3.3 Global CD20 Target Drug Sale Price by Company
3.4 Key Manufacturers CD20 Target Drug Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers CD20 Target Drug Product Location Distribution
3.4.2 Players CD20 Target Drug Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for CD20 Target Drug by Geographic Region
4.1 World Historic CD20 Target Drug Market Size by Geographic Region (2018-2023)
4.1.1 Global CD20 Target Drug Annual Sales by Geographic Region (2018-2023)
4.1.2 Global CD20 Target Drug Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic CD20 Target Drug Market Size by Country/Region (2018-2023)
4.2.1 Global CD20 Target Drug Annual Sales by Country/Region (2018-2023)
4.2.2 Global CD20 Target Drug Annual Revenue by Country/Region (2018-2023)
4.3 Americas CD20 Target Drug Sales Growth
4.4 APAC CD20 Target Drug Sales Growth
4.5 Europe CD20 Target Drug Sales Growth
4.6 Middle East & Africa CD20 Target Drug Sales Growth
5 Americas
5.1 Americas CD20 Target Drug Sales by Country
5.1.1 Americas CD20 Target Drug Sales by Country (2018-2023)
5.1.2 Americas CD20 Target Drug Revenue by Country (2018-2023)
5.2 Americas CD20 Target Drug Sales by Type
5.3 Americas CD20 Target Drug Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC CD20 Target Drug Sales by Region
6.1.1 APAC CD20 Target Drug Sales by Region (2018-2023)
6.1.2 APAC CD20 Target Drug Revenue by Region (2018-2023)
6.2 APAC CD20 Target Drug Sales by Type
6.3 APAC CD20 Target Drug Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe CD20 Target Drug by Country
7.1.1 Europe CD20 Target Drug Sales by Country (2018-2023)
7.1.2 Europe CD20 Target Drug Revenue by Country (2018-2023)
7.2 Europe CD20 Target Drug Sales by Type
7.3 Europe CD20 Target Drug Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa CD20 Target Drug by Country
8.1.1 Middle East & Africa CD20 Target Drug Sales by Country (2018-2023)
8.1.2 Middle East & Africa CD20 Target Drug Revenue by Country (2018-2023)
8.2 Middle East & Africa CD20 Target Drug Sales by Type
8.3 Middle East & Africa CD20 Target Drug Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of CD20 Target Drug
10.3 Manufacturing Process Analysis of CD20 Target Drug
10.4 Industry Chain Structure of CD20 Target Drug
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 CD20 Target Drug Distributors
11.3 CD20 Target Drug Customer
12 World Forecast Review for CD20 Target Drug by Geographic Region
12.1 Global CD20 Target Drug Market Size Forecast by Region
12.1.1 Global CD20 Target Drug Forecast by Region (2024-2029)
12.1.2 Global CD20 Target Drug Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global CD20 Target Drug Forecast by Type
12.7 Global CD20 Target Drug Forecast by Application
13 Key Players Analysis
13.1 Roche
13.1.1 Roche Company Information
13.1.2 Roche CD20 Target Drug Product Portfolios and Specifications
13.1.3 Roche CD20 Target Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Roche Main Business Overview
13.1.5 Roche Latest Developments
13.2 Sanofi
13.2.1 Sanofi Company Information
13.2.2 Sanofi CD20 Target Drug Product Portfolios and Specifications
13.2.3 Sanofi CD20 Target Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Sanofi Main Business Overview
13.2.5 Sanofi Latest Developments
13.3 Novartis
13.3.1 Novartis Company Information
13.3.2 Novartis CD20 Target Drug Product Portfolios and Specifications
13.3.3 Novartis CD20 Target Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Novartis Main Business Overview
13.3.5 Novartis Latest Developments
13.4 TG Therapeutics
13.4.1 TG Therapeutics Company Information
13.4.2 TG Therapeutics CD20 Target Drug Product Portfolios and Specifications
13.4.3 TG Therapeutics CD20 Target Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 TG Therapeutics Main Business Overview
13.4.5 TG Therapeutics Latest Developments
13.5 AbbVie
13.5.1 AbbVie Company Information
13.5.2 AbbVie CD20 Target Drug Product Portfolios and Specifications
13.5.3 AbbVie CD20 Target Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 AbbVie Main Business Overview
13.5.5 AbbVie Latest Developments
13.6 Genmab
13.6.1 Genmab Company Information
13.6.2 Genmab CD20 Target Drug Product Portfolios and Specifications
13.6.3 Genmab CD20 Target Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Genmab Main Business Overview
13.6.5 Genmab Latest Developments
13.7 PT Kalbe Genexine Biologics
13.7.1 PT Kalbe Genexine Biologics Company Information
13.7.2 PT Kalbe Genexine Biologics CD20 Target Drug Product Portfolios and Specifications
13.7.3 PT Kalbe Genexine Biologics CD20 Target Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 PT Kalbe Genexine Biologics Main Business Overview
13.7.5 PT Kalbe Genexine Biologics Latest Developments
13.8 Amgen, Inc.
13.8.1 Amgen, Inc. Company Information
13.8.2 Amgen, Inc. CD20 Target Drug Product Portfolios and Specifications
13.8.3 Amgen, Inc. CD20 Target Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Amgen, Inc. Main Business Overview
13.8.5 Amgen, Inc. Latest Developments
13.9 Pfizer Inc.
13.9.1 Pfizer Inc. Company Information
13.9.2 Pfizer Inc. CD20 Target Drug Product Portfolios and Specifications
13.9.3 Pfizer Inc. CD20 Target Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Pfizer Inc. Main Business Overview
13.9.5 Pfizer Inc. Latest Developments
13.10 Sandoz, Inc.
13.10.1 Sandoz, Inc. Company Information
13.10.2 Sandoz, Inc. CD20 Target Drug Product Portfolios and Specifications
13.10.3 Sandoz, Inc. CD20 Target Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Sandoz, Inc. Main Business Overview
13.10.5 Sandoz, Inc. Latest Developments
13.11 Celltrion, Inc.
13.11.1 Celltrion, Inc. Company Information
13.11.2 Celltrion, Inc. CD20 Target Drug Product Portfolios and Specifications
13.11.3 Celltrion, Inc. CD20 Target Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 Celltrion, Inc. Main Business Overview
13.11.5 Celltrion, Inc. Latest Developments
13.12 Biocad Medical, Inc.
13.12.1 Biocad Medical, Inc. Company Information
13.12.2 Biocad Medical, Inc. CD20 Target Drug Product Portfolios and Specifications
13.12.3 Biocad Medical, Inc. CD20 Target Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 Biocad Medical, Inc. Main Business Overview
13.12.5 Biocad Medical, Inc. Latest Developments
13.13 mAbxience SA
13.13.1 mAbxience SA Company Information
13.13.2 mAbxience SA CD20 Target Drug Product Portfolios and Specifications
13.13.3 mAbxience SA CD20 Target Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.13.4 mAbxience SA Main Business Overview
13.13.5 mAbxience SA Latest Developments
13.14 Hetero Drugs Ltd.
13.14.1 Hetero Drugs Ltd. Company Information
13.14.2 Hetero Drugs Ltd. CD20 Target Drug Product Portfolios and Specifications
13.14.3 Hetero Drugs Ltd. CD20 Target Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.14.4 Hetero Drugs Ltd. Main Business Overview
13.14.5 Hetero Drugs Ltd. Latest Developments
13.15 Aryogen Pharmed
13.15.1 Aryogen Pharmed Company Information
13.15.2 Aryogen Pharmed CD20 Target Drug Product Portfolios and Specifications
13.15.3 Aryogen Pharmed CD20 Target Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.15.4 Aryogen Pharmed Main Business Overview
13.15.5 Aryogen Pharmed Latest Developments
13.16 Biosidus SA
13.16.1 Biosidus SA Company Information
13.16.2 Biosidus SA CD20 Target Drug Product Portfolios and Specifications
13.16.3 Biosidus SA CD20 Target Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.16.4 Biosidus SA Main Business Overview
13.16.5 Biosidus SA Latest Developments
13.17 Probiomed SA de CV
13.17.1 Probiomed SA de CV Company Information
13.17.2 Probiomed SA de CV CD20 Target Drug Product Portfolios and Specifications
13.17.3 Probiomed SA de CV CD20 Target Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.17.4 Probiomed SA de CV Main Business Overview
13.17.5 Probiomed SA de CV Latest Developments
13.18 Henlius
13.18.1 Henlius Company Information
13.18.2 Henlius CD20 Target Drug Product Portfolios and Specifications
13.18.3 Henlius CD20 Target Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.18.4 Henlius Main Business Overview
13.18.5 Henlius Latest Developments
13.19 Innovent
13.19.1 Innovent Company Information
13.19.2 Innovent CD20 Target Drug Product Portfolios and Specifications
13.19.3 Innovent CD20 Target Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.19.4 Innovent Main Business Overview
13.19.5 Innovent Latest Developments
13.20 CHIATAI TIANOING
13.20.1 CHIATAI TIANOING Company Information
13.20.2 CHIATAI TIANOING CD20 Target Drug Product Portfolios and Specifications
13.20.3 CHIATAI TIANOING CD20 Target Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.20.4 CHIATAI TIANOING Main Business Overview
13.20.5 CHIATAI TIANOING Latest Developments
13.21 CASI Pharmaceuticals
13.21.1 CASI Pharmaceuticals Company Information
13.21.2 CASI Pharmaceuticals CD20 Target Drug Product Portfolios and Specifications
13.21.3 CASI Pharmaceuticals CD20 Target Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.21.4 CASI Pharmaceuticals Main Business Overview
13.21.5 CASI Pharmaceuticals Latest Developments
13.22 SinoCellTech
13.22.1 SinoCellTech Company Information
13.22.2 SinoCellTech CD20 Target Drug Product Portfolios and Specifications
13.22.3 SinoCellTech CD20 Target Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.22.4 SinoCellTech Main Business Overview
13.22.5 SinoCellTech Latest Developments
13.23 BioRay
13.23.1 BioRay Company Information
13.23.2 BioRay CD20 Target Drug Product Portfolios and Specifications
13.23.3 BioRay CD20 Target Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.23.4 BioRay Main Business Overview
13.23.5 BioRay Latest Developments
14 Research Findings and Conclusion

 

ページTOPに戻る


 

Summary

According to our LPI (LP Information) latest study, the global CD20 Target Drug market size was valued at US$ million in 2022. With growing demand in downstream market, the CD20 Target Drug is forecast to a readjusted size of US$ million by 2029 with a CAGR of % during review period.
The research report highlights the growth potential of the global CD20 Target Drug market. CD20 Target Drug are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of CD20 Target Drug. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the CD20 Target Drug market.
CD20 is a cell surface antigen that usually appears on the surface of B lymphocytes. CD20-targeted drugs are a class of drugs used to treat specific types of B cell-related diseases. These drugs affect the survival and function of B cells by targeting the CD20 antigen. These drugs are primarily used to treat B-cell lymphoma and autoimmune diseases.
Key Features:
The report on CD20 Target Drug market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the CD20 Target Drug market. It may include historical data, market segmentation by Type (e.g., CD20 Target, CD20+CD3 Target), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the CD20 Target Drug market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the CD20 Target Drug market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the CD20 Target Drug industry. This include advancements in CD20 Target Drug technology, CD20 Target Drug new entrants, CD20 Target Drug new investment, and other innovations that are shaping the future of CD20 Target Drug.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the CD20 Target Drug market. It includes factors influencing customer ' purchasing decisions, preferences for CD20 Target Drug product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the CD20 Target Drug market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting CD20 Target Drug market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the CD20 Target Drug market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the CD20 Target Drug industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the CD20 Target Drug market.
Market Segmentation:
CD20 Target Drug market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Segmentation by type
CD20 Target
CD20+CD3 Target
Segmentation by application
Rheumatoid Arthritis
Chronic Lymphocytic Leukemia
Lymphoma
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Roche
Sanofi
Novartis
TG Therapeutics
AbbVie
Genmab
PT Kalbe Genexine Biologics
Amgen, Inc.
Pfizer Inc.
Sandoz, Inc.
Celltrion, Inc.
Biocad Medical, Inc.
mAbxience SA
Hetero Drugs Ltd.
Aryogen Pharmed
Biosidus SA
Probiomed SA de CV
Henlius
Innovent
CHIATAI TIANOING
CASI Pharmaceuticals
SinoCellTech
BioRay
Key Questions Addressed in this Report
What is the 10-year outlook for the global CD20 Target Drug market?
What factors are driving CD20 Target Drug market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do CD20 Target Drug market opportunities vary by end market size?
How does CD20 Target Drug break out type, application?



ページTOPに戻る


Table of Contents

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global CD20 Target Drug Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for CD20 Target Drug by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for CD20 Target Drug by Country/Region, 2018, 2022 & 2029
2.2 CD20 Target Drug Segment by Type
2.2.1 CD20 Target
2.2.2 CD20+CD3 Target
2.3 CD20 Target Drug Sales by Type
2.3.1 Global CD20 Target Drug Sales Market Share by Type (2018-2023)
2.3.2 Global CD20 Target Drug Revenue and Market Share by Type (2018-2023)
2.3.3 Global CD20 Target Drug Sale Price by Type (2018-2023)
2.4 CD20 Target Drug Segment by Application
2.4.1 Rheumatoid Arthritis
2.4.2 Chronic Lymphocytic Leukemia
2.4.3 Lymphoma
2.4.4 Other
2.5 CD20 Target Drug Sales by Application
2.5.1 Global CD20 Target Drug Sale Market Share by Application (2018-2023)
2.5.2 Global CD20 Target Drug Revenue and Market Share by Application (2018-2023)
2.5.3 Global CD20 Target Drug Sale Price by Application (2018-2023)
3 Global CD20 Target Drug by Company
3.1 Global CD20 Target Drug Breakdown Data by Company
3.1.1 Global CD20 Target Drug Annual Sales by Company (2018-2023)
3.1.2 Global CD20 Target Drug Sales Market Share by Company (2018-2023)
3.2 Global CD20 Target Drug Annual Revenue by Company (2018-2023)
3.2.1 Global CD20 Target Drug Revenue by Company (2018-2023)
3.2.2 Global CD20 Target Drug Revenue Market Share by Company (2018-2023)
3.3 Global CD20 Target Drug Sale Price by Company
3.4 Key Manufacturers CD20 Target Drug Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers CD20 Target Drug Product Location Distribution
3.4.2 Players CD20 Target Drug Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for CD20 Target Drug by Geographic Region
4.1 World Historic CD20 Target Drug Market Size by Geographic Region (2018-2023)
4.1.1 Global CD20 Target Drug Annual Sales by Geographic Region (2018-2023)
4.1.2 Global CD20 Target Drug Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic CD20 Target Drug Market Size by Country/Region (2018-2023)
4.2.1 Global CD20 Target Drug Annual Sales by Country/Region (2018-2023)
4.2.2 Global CD20 Target Drug Annual Revenue by Country/Region (2018-2023)
4.3 Americas CD20 Target Drug Sales Growth
4.4 APAC CD20 Target Drug Sales Growth
4.5 Europe CD20 Target Drug Sales Growth
4.6 Middle East & Africa CD20 Target Drug Sales Growth
5 Americas
5.1 Americas CD20 Target Drug Sales by Country
5.1.1 Americas CD20 Target Drug Sales by Country (2018-2023)
5.1.2 Americas CD20 Target Drug Revenue by Country (2018-2023)
5.2 Americas CD20 Target Drug Sales by Type
5.3 Americas CD20 Target Drug Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC CD20 Target Drug Sales by Region
6.1.1 APAC CD20 Target Drug Sales by Region (2018-2023)
6.1.2 APAC CD20 Target Drug Revenue by Region (2018-2023)
6.2 APAC CD20 Target Drug Sales by Type
6.3 APAC CD20 Target Drug Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe CD20 Target Drug by Country
7.1.1 Europe CD20 Target Drug Sales by Country (2018-2023)
7.1.2 Europe CD20 Target Drug Revenue by Country (2018-2023)
7.2 Europe CD20 Target Drug Sales by Type
7.3 Europe CD20 Target Drug Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa CD20 Target Drug by Country
8.1.1 Middle East & Africa CD20 Target Drug Sales by Country (2018-2023)
8.1.2 Middle East & Africa CD20 Target Drug Revenue by Country (2018-2023)
8.2 Middle East & Africa CD20 Target Drug Sales by Type
8.3 Middle East & Africa CD20 Target Drug Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of CD20 Target Drug
10.3 Manufacturing Process Analysis of CD20 Target Drug
10.4 Industry Chain Structure of CD20 Target Drug
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 CD20 Target Drug Distributors
11.3 CD20 Target Drug Customer
12 World Forecast Review for CD20 Target Drug by Geographic Region
12.1 Global CD20 Target Drug Market Size Forecast by Region
12.1.1 Global CD20 Target Drug Forecast by Region (2024-2029)
12.1.2 Global CD20 Target Drug Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global CD20 Target Drug Forecast by Type
12.7 Global CD20 Target Drug Forecast by Application
13 Key Players Analysis
13.1 Roche
13.1.1 Roche Company Information
13.1.2 Roche CD20 Target Drug Product Portfolios and Specifications
13.1.3 Roche CD20 Target Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Roche Main Business Overview
13.1.5 Roche Latest Developments
13.2 Sanofi
13.2.1 Sanofi Company Information
13.2.2 Sanofi CD20 Target Drug Product Portfolios and Specifications
13.2.3 Sanofi CD20 Target Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Sanofi Main Business Overview
13.2.5 Sanofi Latest Developments
13.3 Novartis
13.3.1 Novartis Company Information
13.3.2 Novartis CD20 Target Drug Product Portfolios and Specifications
13.3.3 Novartis CD20 Target Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Novartis Main Business Overview
13.3.5 Novartis Latest Developments
13.4 TG Therapeutics
13.4.1 TG Therapeutics Company Information
13.4.2 TG Therapeutics CD20 Target Drug Product Portfolios and Specifications
13.4.3 TG Therapeutics CD20 Target Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 TG Therapeutics Main Business Overview
13.4.5 TG Therapeutics Latest Developments
13.5 AbbVie
13.5.1 AbbVie Company Information
13.5.2 AbbVie CD20 Target Drug Product Portfolios and Specifications
13.5.3 AbbVie CD20 Target Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 AbbVie Main Business Overview
13.5.5 AbbVie Latest Developments
13.6 Genmab
13.6.1 Genmab Company Information
13.6.2 Genmab CD20 Target Drug Product Portfolios and Specifications
13.6.3 Genmab CD20 Target Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Genmab Main Business Overview
13.6.5 Genmab Latest Developments
13.7 PT Kalbe Genexine Biologics
13.7.1 PT Kalbe Genexine Biologics Company Information
13.7.2 PT Kalbe Genexine Biologics CD20 Target Drug Product Portfolios and Specifications
13.7.3 PT Kalbe Genexine Biologics CD20 Target Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 PT Kalbe Genexine Biologics Main Business Overview
13.7.5 PT Kalbe Genexine Biologics Latest Developments
13.8 Amgen, Inc.
13.8.1 Amgen, Inc. Company Information
13.8.2 Amgen, Inc. CD20 Target Drug Product Portfolios and Specifications
13.8.3 Amgen, Inc. CD20 Target Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Amgen, Inc. Main Business Overview
13.8.5 Amgen, Inc. Latest Developments
13.9 Pfizer Inc.
13.9.1 Pfizer Inc. Company Information
13.9.2 Pfizer Inc. CD20 Target Drug Product Portfolios and Specifications
13.9.3 Pfizer Inc. CD20 Target Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Pfizer Inc. Main Business Overview
13.9.5 Pfizer Inc. Latest Developments
13.10 Sandoz, Inc.
13.10.1 Sandoz, Inc. Company Information
13.10.2 Sandoz, Inc. CD20 Target Drug Product Portfolios and Specifications
13.10.3 Sandoz, Inc. CD20 Target Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Sandoz, Inc. Main Business Overview
13.10.5 Sandoz, Inc. Latest Developments
13.11 Celltrion, Inc.
13.11.1 Celltrion, Inc. Company Information
13.11.2 Celltrion, Inc. CD20 Target Drug Product Portfolios and Specifications
13.11.3 Celltrion, Inc. CD20 Target Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 Celltrion, Inc. Main Business Overview
13.11.5 Celltrion, Inc. Latest Developments
13.12 Biocad Medical, Inc.
13.12.1 Biocad Medical, Inc. Company Information
13.12.2 Biocad Medical, Inc. CD20 Target Drug Product Portfolios and Specifications
13.12.3 Biocad Medical, Inc. CD20 Target Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 Biocad Medical, Inc. Main Business Overview
13.12.5 Biocad Medical, Inc. Latest Developments
13.13 mAbxience SA
13.13.1 mAbxience SA Company Information
13.13.2 mAbxience SA CD20 Target Drug Product Portfolios and Specifications
13.13.3 mAbxience SA CD20 Target Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.13.4 mAbxience SA Main Business Overview
13.13.5 mAbxience SA Latest Developments
13.14 Hetero Drugs Ltd.
13.14.1 Hetero Drugs Ltd. Company Information
13.14.2 Hetero Drugs Ltd. CD20 Target Drug Product Portfolios and Specifications
13.14.3 Hetero Drugs Ltd. CD20 Target Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.14.4 Hetero Drugs Ltd. Main Business Overview
13.14.5 Hetero Drugs Ltd. Latest Developments
13.15 Aryogen Pharmed
13.15.1 Aryogen Pharmed Company Information
13.15.2 Aryogen Pharmed CD20 Target Drug Product Portfolios and Specifications
13.15.3 Aryogen Pharmed CD20 Target Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.15.4 Aryogen Pharmed Main Business Overview
13.15.5 Aryogen Pharmed Latest Developments
13.16 Biosidus SA
13.16.1 Biosidus SA Company Information
13.16.2 Biosidus SA CD20 Target Drug Product Portfolios and Specifications
13.16.3 Biosidus SA CD20 Target Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.16.4 Biosidus SA Main Business Overview
13.16.5 Biosidus SA Latest Developments
13.17 Probiomed SA de CV
13.17.1 Probiomed SA de CV Company Information
13.17.2 Probiomed SA de CV CD20 Target Drug Product Portfolios and Specifications
13.17.3 Probiomed SA de CV CD20 Target Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.17.4 Probiomed SA de CV Main Business Overview
13.17.5 Probiomed SA de CV Latest Developments
13.18 Henlius
13.18.1 Henlius Company Information
13.18.2 Henlius CD20 Target Drug Product Portfolios and Specifications
13.18.3 Henlius CD20 Target Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.18.4 Henlius Main Business Overview
13.18.5 Henlius Latest Developments
13.19 Innovent
13.19.1 Innovent Company Information
13.19.2 Innovent CD20 Target Drug Product Portfolios and Specifications
13.19.3 Innovent CD20 Target Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.19.4 Innovent Main Business Overview
13.19.5 Innovent Latest Developments
13.20 CHIATAI TIANOING
13.20.1 CHIATAI TIANOING Company Information
13.20.2 CHIATAI TIANOING CD20 Target Drug Product Portfolios and Specifications
13.20.3 CHIATAI TIANOING CD20 Target Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.20.4 CHIATAI TIANOING Main Business Overview
13.20.5 CHIATAI TIANOING Latest Developments
13.21 CASI Pharmaceuticals
13.21.1 CASI Pharmaceuticals Company Information
13.21.2 CASI Pharmaceuticals CD20 Target Drug Product Portfolios and Specifications
13.21.3 CASI Pharmaceuticals CD20 Target Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.21.4 CASI Pharmaceuticals Main Business Overview
13.21.5 CASI Pharmaceuticals Latest Developments
13.22 SinoCellTech
13.22.1 SinoCellTech Company Information
13.22.2 SinoCellTech CD20 Target Drug Product Portfolios and Specifications
13.22.3 SinoCellTech CD20 Target Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.22.4 SinoCellTech Main Business Overview
13.22.5 SinoCellTech Latest Developments
13.23 BioRay
13.23.1 BioRay Company Information
13.23.2 BioRay CD20 Target Drug Product Portfolios and Specifications
13.23.3 BioRay CD20 Target Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.23.4 BioRay Main Business Overview
13.23.5 BioRay Latest Developments
14 Research Findings and Conclusion

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります


よくあるご質問


LP Information社はどのような調査会社ですか?


LP Informationは通信、エネルギー、医薬をはじめとする広範な市場の調査とレポート出版を行っている調査会社です。 もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/06/21 10:26

160.10 円

171.83 円

205.37 円

ページTOPに戻る